A new study published in the journal of The Lancet Infectious Diseases showed that an efficient substitute for current COVID-19 therapies is ensitrelvir, a once-daily oral SARS-CoV-2 protease inhibitor developed by Shionogi. The current oral first-line medication for COVID-19, ritonavir-boosted nirmatrelvir, shares a molecular target (the primary protease) with ensitrelvir.

Ensitrelvir Shows Promise as Effective COVID-19 Antiviral in Phase 2 Trial

Pfizer’s oral COVID-19 antiviral Paxlovid received expanded approval from South Korea’s Ministry of Food and Drug Safety for use in patients with severe renal impairment, broadening the eligible treatment population.

Pfizer's Covid pill Paxlovid wins expanded MFDS nod for severe renal impairment patients

The Indian government enforced a ban on oral nimesulide above 100 mg following ICMR advice, citing liver toxicity and public health risks.

Govt bans manufacture, sale of oral formulations containing nimesulide above 100 mg-Here's why

India’s health ministry banned oral formulations of nimesulide above 100 mg due to safety concerns, including liver toxicity, citing availability of safer alternatives.

India bans oral Nimesulide over 100 mg

Following recommendations from ICMR, the Indian government halted the manufacture and sale of high-dose oral nimesulide formulations over safety risks.

antiviral news

Press Releases in the global landscape